Hot Products

Arecoline hydrobromide
Catalog No: CFN90799

Arecoline hydrobromide is formerly used as a cholinergic agent, it is a hypotensive agent. Arecoline hydrobromide is purgative, vermifuge and taenifuge agents in veterinary medicine. It induces rat hepatic CYP2 B by promoting nuclear translocation of CAR, the regulation of it on rat hepatic CYP2 B largely involve transcriptional activation of the gene,partially involve the post-translational modification of CYP2 B protein.

Arenobufagin
Catalog No: CFN98578

Arenobufagin is a potent Na + /K + pump inhibitor, and is also a specific inhibitor of VEGF-mediated angiogenesis. Arenobufagin has antineoplastic effect that involves cross talk between apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathway.

Arganine B
Catalog No: CFN95281

Arglabin
Catalog No: CFN89201

Arglabin has antiatherogenic effects, it may represent a new promising compound to treat inflammation and type 2 diabetes mellitus development, it can attenuate inflammation, protect pancreatic β-cells from apoptosis, and prevent Type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. Arglabin shows promising antitumor activity against different tumor cell lines, Arglabin-DMA inhibits cell proliferation of a variety of tumor types with IC(90)s in the range of 0.85 to 5.0 microg/ml.

Aristola-1(10),8-dien-2-one
Catalog No: CFN89328

Reference standards.

Aristolactam AII
Catalog No: CFN96013

Aristolactam AII has cytotoxic activity, it also shows platelet aggregation inhibitory activity.

Aristolactam AIIIa
Catalog No: CFN97551

Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid.

Aristolactam BII
Catalog No: CFN98903

Aristolactam BII exhibits antimicrobial and antiinflammatory activity, it shows significant activity towards DPPH radical scavenging and potent inhibitory effects against tyrosinase mushroom. Aristolactam BII also exerts its significant neuroprotective effects on glutamate-injured primary cultures of rat cortical cells by directly inhibiting the production of nitric oxide.

Aristolactam BIII
Catalog No: CFN98904

Aristolactam BIII possesses anti-platelet aggregation activity in vitro, it also shows significant cytotoxic activity (IC50 values < 4 microg/mL) against P-388, HT-29 and A549 cell lines in vitro.

Aristolactam FI
Catalog No: CFN99222

Aristolactam FI shows platelet aggregation inhibitory activity.It is a potential cancer chemotherapeutic and chemopreventive agent.